LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

Search

MacroGenics Inc

Chiusa

SettoreSettore sanitario

1.46 -6.41

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.44

Massimo

1.56

Metriche Chiave

By Trading Economics

Entrata

-26M

-41M

Vendite

-4.5M

13M

P/E

Media del settore

38.83

54.533

EPS

-0.65

Margine di Profitto

-311.067

Dipendenti

341

EBITDA

-30M

-43M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+167.52% upside

Dividendi

By Dow Jones

Utili prossimi

4 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-53M

100M

Apertura precedente

7.87

Chiusura precedente

1.46

Notizie sul Sentiment di mercato

By Acuity

50%

50%

187 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

MacroGenics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 mag 2025, 23:25 UTC

Azioni calde

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21 mag 2025, 21:57 UTC

Acquisizioni, Fusioni, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21 mag 2025, 21:29 UTC

Acquisizioni, Fusioni, Takeovers

Millicom to Acquire Telefónica's Operations in Uruguay

21 mag 2025, 21:01 UTC

I principali Market Mover

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21 mag 2025, 20:51 UTC

Acquisizioni, Fusioni, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion

21 mag 2025, 23:49 UTC

Discorsi di Mercato

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21 mag 2025, 23:37 UTC

Discorsi di Mercato

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21 mag 2025, 23:33 UTC

Acquisizioni, Fusioni, Takeovers

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 mag 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 mag 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 mag 2025, 23:32 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21 mag 2025, 23:31 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21 mag 2025, 23:30 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21 mag 2025, 23:30 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21 mag 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21 mag 2025, 23:28 UTC

Utili

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21 mag 2025, 23:27 UTC

Utili

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21 mag 2025, 23:26 UTC

Utili

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21 mag 2025, 23:26 UTC

Utili

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21 mag 2025, 23:26 UTC

Utili

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21 mag 2025, 23:23 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 mag 2025, 23:22 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 mag 2025, 23:20 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 mag 2025, 23:18 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21 mag 2025, 21:42 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21 mag 2025, 21:14 UTC

Acquisizioni, Fusioni, Takeovers

Millicom to Acquire Telefónica's Ops in Uruguay

21 mag 2025, 21:07 UTC

Notizie principali

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21 mag 2025, 21:06 UTC

Acquisizioni, Fusioni, Takeovers

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

21 mag 2025, 20:59 UTC

Notizie principali

Walmart to Cut 1,500 Jobs -- WSJ

21 mag 2025, 20:52 UTC

Utili

Snowflake Stock Pops After Earnings Beat -- Barrons.com

Confronto tra pari

Modifica del prezzo

MacroGenics Inc Previsione

Obiettivo di Prezzo

By TipRanks

167.52% in crescita

Previsioni per 12 mesi

Media 4.2 USD  167.52%

Alto 8 USD

Basso 2 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per MacroGenics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

8 ratings

2

Acquista

6

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.47 / 1.64Supporto e resistenza

A breve termine

Neutral Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

187 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.